<a href="https://laohu8.com/S/TEM">Tempus AI</a> Inc. Secures FDA 510(k) Clearance for AI-Driven Tempus ECG-Low EF Software to Enhance Cardiovascular Risk Detection
Tempus AI Inc. has announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Tempus ECG-Low EF software. This advanced AI-driven tool is designed to identify patients who may have a low left ventricular ejection fraction (LVEF), which is crucial for diagnosing serious cardiovascular conditions. This clearance marks the second FDA-approved ECG-AI device in Tempus' suite of cardiology tools, following the Tempus ECG-AF. The software is intended for use in clinical settings for patients aged 40 and above who are at risk of heart failure, and it aids in the detection of signs associated with low LVEF. This achievement underscores Tempus' commitment to leveraging AI to enhance precision medicine and patient care.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tempus AI Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250716917042) on July 16, 2025, and is solely responsible for the information contained therein.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。